Study summary · 2022 · Evidence review
Economic evaluations of RPM across chronic diseases
Economic value depended on the condition, delivery costs, perspective and local willingness to pay.
Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence
Original publication
Economic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review
Keshia R De Guzman; Centaine L Snoswell; Monica L Taylor; Leonard C Gray; Liam J Caffery
Centre for Online Health and Centre for Health Services Research, University of Queensland, Australia
Value in Health · Online: · Issue: June 2022
Journal version of record. · Full text consulted.
What was studied
- Design
- Evidence review
- Population
- People with chronic diseases
- Sample
- 34 economic evaluations
- Intervention
- Non-invasive RPM
- Comparator
- Usual care
- Follow-up
- Economic horizons varied
- Review search cutoff
- 2021-09
- Setting
- Multiple countries
Methods
Systematic review of economic evaluations; CHEERS assessed reporting completeness, not freedom from model bias.
Findings
Hypertension evaluations generally favored RPM. Heart-failure and COPD conclusions varied by setting and disease severity; diabetes evidence was limited.
Limitations
Heterogeneity prevented meta-analysis. Publication bias and incomplete capital-cost or payback reporting limit transferability.
What this means for care delivery
Cost-effectiveness can coexist with higher spending; calculate local staffing, setup and ongoing costs before projecting savings.